Research Article
Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer
Table 1
Characteristics of the study population.
| | Characteristics | Numbers of cases (%) |
| | Age | | NA | 2 (0.18) | | <60 | 589 (53.35) | | ≥60 | 513 (46.47) | | Gender | | NA | 2 (0.18) | | Female | 1090 (98.73) | | Male | 12 (1.09) | | Histological type | | NA | 3 (0.27) | | Infiltrating ductal carcinoma | 790 (71.56) | | Infiltrating lobular carcinoma | 204 (18.48) | | Other | 107 (9.69) | | Molecular subtype | | NA | 255 (23.1) | | Basal | 142 (12.86) | | HER-2 | 67 (6.07) | | Luminal A | 422 (38.22) | | Luminal B | 194 (17.57) | | Normal | 24 (2.17) | | ER | | NA | 50 (4.53) | | Indeterminate | 2 (0.18) | | Negative | 239 (21.65) | | Positive | 813 (73.64) | | PR | | NA | 51 (4.62) | | Indeterminate | 4 (0.36) | | Negative | 345 (31.25) | | Positive | 704 (63.77) | | HER-2 | | NA | 183 (16.58) | | Equivocal | 180 (16.3) | | Indeterminate | 12 (1.09) | | Negative | 565 (51.18) | | Positive | 164 (14.86) | | Menopause status | | NA | 93 (8.42) | | Indeterminate | 34 (3.08) | | Peri | 40 (3.62) | | Post | 706 (63.95) | | Pre | 231 (20.92) | | T classification | | NA | 2 (0.18) | | T1 | 281 (25.45) | | T2 | 640 (57.97) | | T3 | 138 (12.5) | | T4 | 40 (3.62) | | TX | 3 (0.27) | | N classification | | NA | 2 (0.18) | | N0 | 516 (46.74) | | N1 | 367 (33.24) | | N2 | 120 (10.87) | | N3 | 79 (7.16) | | NX | 20 (1.81) | | M classification | | NA | 2 (0.18) | | M0 | 917 (83.06) | | M1 | 22 (1.99) | | MX | 163 (14.76) | | TNM stage | | | NA | 10 (0.91) | | I | 182 (16.49) | | II | 626 (56.7) | | III | 252 (22.83) | | IV | 20 (1.81) | | X | 14 (1.27) | | Margin status | | NA | 72 (6.52) | | Close | 31 (2.81) | | Negative | 922 (83.51) | | Positive | 79 (7.16) | | Vital status | | NA | 2 (0.18) | | Deceased | 155 (14.04) | | Living | 947 (85.78) | | Radiation therapy | | NA | 102 (9.24) | | No | 445 (40.31) | | Yes | 557 (50.45) | | Neoadjuvant treatment | | NA | 3 (0.27) | | No | 1088 (98.55) | | Yes | 13 (1.18) | | Targeted molecular therapy | | NA | 525 (47.55) | | No | 46 (4.17) | | Yes | 533 (48.28) | | Sample type | | Metastatic | 7 (0.63) | | Primary tumor | 1097 (99.37) | | OS | | | NA | 17 (1.54) | | 0 | 933 (84.51) | | 1 | 154 (13.95) | | RFS | | NA | 192 (17.39) | | 0 | 816 (73.91) | | 1 | 96 (8.70) | | ZNF385B | | High | 804 (72.83) | | Low | 300 (27.17) |
|
|
ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor-2; T: tumor; M: metastasis; N: node; OS: overall survival; RFS: relapse-free survival; NA: not available.
|
